Victory Capital Management
STML

Victory Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Victory Capital Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-127,270
Closed -$616K – 3696
2020
Q1 		$616K Buy
127,270
+56,775
+81% +$368K ﹤0.01% 2018
2019
Q4 		$749K Buy
70,495
+2,133
+3% +$21.2K ﹤0.01% 1837
2019
Q3 		$712K Buy
68,362
+66,753
+4,149% +$873K ﹤0.01% 1777
2019
Q2 		$25K Hold
1,609
– – ﹤0.01% 1786
2019
Q1 		$21K Hold
1,609
– – ﹤0.01% 1743
2018
Q4 		$15K Hold
1,609
– – ﹤0.01% 1750
2018
Q3 		$27K Buy
1,609
+211
+15% +$3.38K ﹤0.01% 1743
2018
Q2 		$22K Sell
1,398
-460
-25% -$8.21K ﹤0.01% 1793
2018
Q1 		$28K Hold
1,858
– – ﹤0.01% 1778
2017
Q4 		$29K Hold
1,858
– – ﹤0.01% 1774
2017
Q3 		$21K Hold
1,858
– – ﹤0.01% 1775
2017
Q2 		$17K Buy
+1,858
New +$15.5K ﹤0.01% 1778

Victory Capital Management's STML Position: Q2 2020 in Review

Victory Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 127,270 shares — an estimated $616K sold.

Victory Capital Management first reported a position in STML in Q2 2017 and held it in 12 quarters. The position peaked at $749K in Q4 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

  • Victory Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 127,270 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $616K.
  • Victory Capital Management first reported a position in Stemline Therapeutics, Inc. in Q2 2017 and held it in 12 quarters.
  • Victory Capital Management's Stemline Therapeutics, Inc. position peaked at $749K in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.